Recombinant Chimeric COVID-19 Epitope DC Vaccine; Uses, Dosage, Side Effects and more
The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the recombinant chimeric DC vaccine reduces the risk of virulence recovery, pre-existing anti-vector immunity, and incomplete viral inactivation.
As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
| Trade Name | Recombinant Chimeric COVID-19 Epitope DC Vaccine; |
| Generic | Dendritic cells vaccine |
| Dendritic cells vaccine Other Names | Recombinant chimeric COVID-19 DC vaccine, Recombinant chimeric COVID-19 epitope DC vaccine; |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
